查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1239487

腦脊液管理市場：按類型（腦脊液分流器、外引流系統）、年齡組（兒科、成人）、全球機會分析和行業預測，2021-2031 年

Cerebrospinal Fluid Management Market By Type (CSF shunts, External drainage system), By Age group (Pediatric, Adult): Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 220 Pages | 商品交期: 2-3個工作天內

價格

2021 年腦脊液管理市場價值為 6.7544 億美元，預計到 2031 年將達到 10.3256 億美元，2022 年至 2031 年的複合年增長率為 4.4%。

腦積水是大腦後部腦室內積液。 多餘的液體，稱為腦脊液，會增加腦室的大小並壓迫大腦。 它可以用腦脊液管理裝置進行治療。 腦脊液管理設備包括分流器和外部引流系統等設備，以維持腦脊液的流動並排出大腦中多餘的液體。 顱內壓升高會對中樞神經系統造成不可逆轉的損害。 它可以防止靜脈和動脈血壓以及休克壓的急劇變化。 然而，外傷、腫瘤、感染、神經外科手術和其他因素會增加顱內壓。 手術和非手術治療方法均可用於控制由於外傷和非外傷原因導致的顱內壓升高。 對於因腦損傷導致顱內壓升高的患者，顱內壓監測可客觀評估對治療的反應和壓力動態。 監測部位包括腦室內、腦實質內、蛛網膜下腔和硬膜外，各種裝置各有利弊。

腦脊液管理市場的增長是由於腦外科手術數量的增加、研發數量的快速增加、政府和私人機構產品開發成本的增加、技術的增加腦脊液管理設備的進步和實驗室的增加。帶來的 此外，正常腦脊液循環和旋轉的破壞被認為有助於神經退行性疾□□病的發展，例如阿爾茨海默氏病、缺血性/創傷性腦損傷和神經炎症性疾病，例如多發性硬化症。。 因此，越來越多地採用腦脊液管理設備正在推動市場的增長。 製藥和生物技術研究機構的研究管道不斷增加，以及在存在腦脊液體積紊亂的情況下對調查研究的認識不斷提高，也推動了市場的增長。 例如，根據國家醫學圖書館的一項研究，到 2021 年 6 月，印度將有 687 人接受神經外科手術入院，而 2019 年有 2,550 人住院。 神經外科的手術總數也顯示出類似的趨勢，2020 年只有 654 台手術，而 2019 年有 3165 台手術。 此外，易患神經系統疾病的老齡化人口增加也有助於市場需求。 然而，腦脊液相關疾病的高昂治療費用預計將阻礙市場增長。

內容

第一章介紹

第 2 章執行摘要

第 3 章市場概述

  • 市場定義和範圍
  • 主要發現
    • 主要影響因素
    • 主要投資機會
  • 波特的五力分析
    • 供應商的議價能力
    • 買家的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭激烈程度
  • 市場動態
    • 司機
      • 腦部疾病的患病率增加
      • 不斷增長的老年人口
      • 對 CSF 分流器開發的需求不斷增長
    • 約束因素
      • 與分流相關的並發症
    • 機會
      • 增加研發 (R&D) 活動
  • 分析 COVID-19 對市場的影響

第 4 章腦脊液管理市場：按類型

  • 概覽
    • 市場規模和預測
  • 腦液分流術
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 外部排水系統
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類

第 5 章腦脊液管理市場：按年齡組分類

  • 概覽
    • 市場規模和預測
  • 兒科
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 成人
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類

第 6 章腦脊液管理市場：按地區

  • 概覽
    • 市場規模和預測：按地區
  • 北美
    • 主要趨勢和機會
    • 市場規模和按類型預測
    • 市場規模和預測：按年齡段
    • 市場規模和預測：按國家/地區分類
      • 美國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 市場規模和預測：按年齡段
      • 加拿大
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 市場規模和預測：按年齡段
      • 墨西哥
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 市場規模和預測：按年齡段
  • 歐洲
    • 主要趨勢和機會
    • 市場規模和按類型預測
    • 市場規模和預測：按年齡段
    • 市場規模和預測：按國家/地區分類
      • 德國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 市場規模和預測：按年齡段
      • 法國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 市場規模和預測：按年齡段
      • 英國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 市場規模和預測：按年齡段
      • 意大利
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 市場規模和預測：按年齡段
      • 西班牙
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 市場規模和預測：按年齡段
      • 其他歐洲
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 市場規模和預測：按年齡段
  • 亞太地區
    • 主要趨勢和機會
    • 市場規模和按類型預測
    • 市場規模和預測：按年齡段
    • 市場規模和預測：按國家/地區分類
      • 中國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 市場規模和預測：按年齡段
      • 日本
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 市場規模和預測：按年齡段
      • 印度
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 市場規模和預測：按年齡段
      • 澳大利亞
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 市場規模和預測：按年齡段
      • 韓國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 市場規模和預測：按年齡段
      • 其他亞太地區
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 市場規模和預測：按年齡段
  • 拉丁美洲/中東/非洲
    • 主要趨勢和機會
    • 市場規模和按類型預測
    • 市場規模和預測：按年齡段
    • 市場規模和預測：按國家/地區分類
      • 巴西
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 市場規模和預測：按年齡段
      • 沙特阿拉伯
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 市場規模和預測：按年齡段
      • 南非
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 市場規模和預測：按年齡段
      • 拉丁美洲其他地區/中東/非洲
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和按類型預測
      • 市場規模和預測：按年齡段

第七章競爭格局

  • 介紹
  • 關鍵成功策略
  • 10 家主要公司的產品映射
  • 比賽儀表板
  • 競爭熱圖
  • 2021 年主要公司定位

第八章公司簡介

  • Medtronic plc
  • B. Braun Melsungen AG
  • Integra LifeSciences Holdings
  • Wellona Pharma
  • Delta Surgical
  • Spiegelberg GmbH & Co. KG
  • G. Surgiwear Ltd.
  • Moller Medical GmbH
  • Natus Medical Incorporated
  • Tokibo Co.,Ltd
Product Code: A10924

The Cerebral Spinal Fluid Management Market valued for $675.44 million in 2021 and is estimated to reach $1,032.56 million by 2031, exhibiting a CAGR of 4.4% from 2022 to 2031.  

Hydrocephalus refers to the buildup of fluid in the ventricles deep within the brain. The excess fluid called cerebral spinal fluid increases the size of the ventricles and puts pressure on the brain. It can be treated with the use of cerebral spinal fluid management devices. Cerebrospinal fluid (CSF) management devices involve the devices such as shunts and external drainage systems to maintain the flow of CSF and drain excess fluid from the brain. Increased intracranial pressure can result in irreversible injury to the central nervous system. It provides protection against acute changes in venous and arterial blood pressure or impact pressure. Nevertheless, trauma, tumors, infections, neurosurgical procedures, and other factors can cause increased intracranial pressure. Both surgical and nonsurgical therapeutic modalities can be used in the management of increased intracranial pressure attributable to traumatic and non-traumatic causes. In patients with cerebral injury and increased intracranial pressure, monitoring of the intracranial pressure can provide an objective measure of the response to therapy and the pressure dynamics. Intraventricular, intraparenchymal, subarachnoid, and epidural sites can be used for monitoring, and the advantages and disadvantages of the various devices available. 

The growth of the cerebral spinal fluid management market is driven by increase in the number of brain surgeries, surge in number of research and development activities, rise in expenditure on the product development by the government & private organizations and increase in the technological advancements of the cerebral spinal fluid management devices and increase in the number of research laboratories. Moreover, the disruption of normal cerebral spinal fluid circulation and turnover is believed to contribute to the development of many neurodegenerative conditions such as Alzheimer's disease, ischemic and traumatic brain injury, and neuroinflammatory conditions such as multiple sclerosis. Hence, increase in the adoption of cerebral spinal fluid management devices boosts the growth of the market. In addition, increase in the research pipeline among the pharmaceutical and biotechnology research organizations and surge in awareness about research studies on the conditions of disrupted volume of cerebral spinal fluid foster the growth of the market. For instance, according to the study of National Library of Medicine, in June 2021, there were 687 neurosurgery admissions in India during the study period compared with 2550 admissions in 2019. The total number of surgeries performed in neurosurgery also showed a similar trend, with only 654 surgeries in 2020 compared with 3165 surgeries in 2019. Moreover, increase in the geriatric population which are more prone to the neurological disorders are also contributing in the demand of the market. However, the high cost of the treatment for cerebral spinal fluid related diseases is expected to hinder the growth of the market. 

The cerebral spinal fluid management market is segmented on the basis of type, age group and region. On the basis of type, the market is bifurcated into CSF shunts and external drainage system. On the basis of age group, the market is classified into pediatric and adult. Region wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA). 

Major companies profiled in the report include: B. Braun Melsungen AG, Delta Surgical, G. SURGIWEAR LTD, Integra Lifesciences Holdings, Medtronic plc, Moller Medical GMBH, Natus Medical Incorporated, Spiegelberg GmbH & Co. KG, Tokibo Co., Ltd., and Wellong Pharma. 

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the cerebral spinal fluid management market analysis from 2021 to 2031 to identify the prevailing cerebral spinal fluid management market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the cerebral spinal fluid management market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global cerebral spinal fluid management market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Type

  • CSF shunts
  • External drainage system

By Age group

  • Pediatric
  • Adult

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players

  • B. Braun Melsungen AG
  • Delta Surgical
  • Spiegelberg GmbH & Co. KG
  • Moller Medical GmbH
  • Tokibo Co.,Ltd
  • Medtronic plc
  • G. Surgiwear Ltd.
  • Integra LifeSciences Holdings
  • Wellona Pharma
  • Natus Medical Incorporated

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Bargaining power of suppliers
    • 3.3.2. Bargaining power of buyers
    • 3.3.3. Threat of substitutes
    • 3.3.4. Threat of new entrants
    • 3.3.5. Intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Increase in the prevalence of brain disorders
      • 3.4.1.2. Increase in the geriatric population
      • 3.4.1.3. Rise in demand for development in the CSF shunts
    • 3.4.2. Restraints
      • 3.4.2.1. Complications related to the shunts
    • 3.4.3. Opportunities
      • 3.4.3.1. Rise in the of research and developments (R&D) activities
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. CSF shunts
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. External drainage system
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country

CHAPTER 5: CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Pediatric
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Adult
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: CEREBROSPINAL FLUID MANAGEMENT MARKET, BY REGION

  • 6.1. Overview
    • 6.1.1. Market size and forecast By Region
  • 6.2. North America
    • 6.2.1. Key trends and opportunities
    • 6.2.2. Market size and forecast, by Type
    • 6.2.3. Market size and forecast, by Age group
    • 6.2.4. Market size and forecast, by country
      • 6.2.4.1. U.S.
      • 6.2.4.1.1. Key market trends, growth factors and opportunities
      • 6.2.4.1.2. Market size and forecast, by Type
      • 6.2.4.1.3. Market size and forecast, by Age group
      • 6.2.4.2. Canada
      • 6.2.4.2.1. Key market trends, growth factors and opportunities
      • 6.2.4.2.2. Market size and forecast, by Type
      • 6.2.4.2.3. Market size and forecast, by Age group
      • 6.2.4.3. Mexico
      • 6.2.4.3.1. Key market trends, growth factors and opportunities
      • 6.2.4.3.2. Market size and forecast, by Type
      • 6.2.4.3.3. Market size and forecast, by Age group
  • 6.3. Europe
    • 6.3.1. Key trends and opportunities
    • 6.3.2. Market size and forecast, by Type
    • 6.3.3. Market size and forecast, by Age group
    • 6.3.4. Market size and forecast, by country
      • 6.3.4.1. Germany
      • 6.3.4.1.1. Key market trends, growth factors and opportunities
      • 6.3.4.1.2. Market size and forecast, by Type
      • 6.3.4.1.3. Market size and forecast, by Age group
      • 6.3.4.2. France
      • 6.3.4.2.1. Key market trends, growth factors and opportunities
      • 6.3.4.2.2. Market size and forecast, by Type
      • 6.3.4.2.3. Market size and forecast, by Age group
      • 6.3.4.3. UK
      • 6.3.4.3.1. Key market trends, growth factors and opportunities
      • 6.3.4.3.2. Market size and forecast, by Type
      • 6.3.4.3.3. Market size and forecast, by Age group
      • 6.3.4.4. Italy
      • 6.3.4.4.1. Key market trends, growth factors and opportunities
      • 6.3.4.4.2. Market size and forecast, by Type
      • 6.3.4.4.3. Market size and forecast, by Age group
      • 6.3.4.5. Spain
      • 6.3.4.5.1. Key market trends, growth factors and opportunities
      • 6.3.4.5.2. Market size and forecast, by Type
      • 6.3.4.5.3. Market size and forecast, by Age group
      • 6.3.4.6. Rest of Europe
      • 6.3.4.6.1. Key market trends, growth factors and opportunities
      • 6.3.4.6.2. Market size and forecast, by Type
      • 6.3.4.6.3. Market size and forecast, by Age group
  • 6.4. Asia-Pacific
    • 6.4.1. Key trends and opportunities
    • 6.4.2. Market size and forecast, by Type
    • 6.4.3. Market size and forecast, by Age group
    • 6.4.4. Market size and forecast, by country
      • 6.4.4.1. China
      • 6.4.4.1.1. Key market trends, growth factors and opportunities
      • 6.4.4.1.2. Market size and forecast, by Type
      • 6.4.4.1.3. Market size and forecast, by Age group
      • 6.4.4.2. Japan
      • 6.4.4.2.1. Key market trends, growth factors and opportunities
      • 6.4.4.2.2. Market size and forecast, by Type
      • 6.4.4.2.3. Market size and forecast, by Age group
      • 6.4.4.3. India
      • 6.4.4.3.1. Key market trends, growth factors and opportunities
      • 6.4.4.3.2. Market size and forecast, by Type
      • 6.4.4.3.3. Market size and forecast, by Age group
      • 6.4.4.4. Australia
      • 6.4.4.4.1. Key market trends, growth factors and opportunities
      • 6.4.4.4.2. Market size and forecast, by Type
      • 6.4.4.4.3. Market size and forecast, by Age group
      • 6.4.4.5. South Korea
      • 6.4.4.5.1. Key market trends, growth factors and opportunities
      • 6.4.4.5.2. Market size and forecast, by Type
      • 6.4.4.5.3. Market size and forecast, by Age group
      • 6.4.4.6. Rest of Asia-Pacific
      • 6.4.4.6.1. Key market trends, growth factors and opportunities
      • 6.4.4.6.2. Market size and forecast, by Type
      • 6.4.4.6.3. Market size and forecast, by Age group
  • 6.5. LAMEA
    • 6.5.1. Key trends and opportunities
    • 6.5.2. Market size and forecast, by Type
    • 6.5.3. Market size and forecast, by Age group
    • 6.5.4. Market size and forecast, by country
      • 6.5.4.1. Brazil
      • 6.5.4.1.1. Key market trends, growth factors and opportunities
      • 6.5.4.1.2. Market size and forecast, by Type
      • 6.5.4.1.3. Market size and forecast, by Age group
      • 6.5.4.2. Saudi Arabia
      • 6.5.4.2.1. Key market trends, growth factors and opportunities
      • 6.5.4.2.2. Market size and forecast, by Type
      • 6.5.4.2.3. Market size and forecast, by Age group
      • 6.5.4.3. South Africa
      • 6.5.4.3.1. Key market trends, growth factors and opportunities
      • 6.5.4.3.2. Market size and forecast, by Type
      • 6.5.4.3.3. Market size and forecast, by Age group
      • 6.5.4.4. Rest of LAMEA
      • 6.5.4.4.1. Key market trends, growth factors and opportunities
      • 6.5.4.4.2. Market size and forecast, by Type
      • 6.5.4.4.3. Market size and forecast, by Age group

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top winning strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Top player positioning, 2021

CHAPTER 8: COMPANY PROFILES

  • 8.1. Medtronic plc
    • 8.1.1. Company overview
    • 8.1.2. Key Executives
    • 8.1.3. Company snapshot
    • 8.1.4. Operating business segments
    • 8.1.5. Product portfolio
    • 8.1.6. Business performance
  • 8.2. B. Braun Melsungen AG
    • 8.2.1. Company overview
    • 8.2.2. Key Executives
    • 8.2.3. Company snapshot
    • 8.2.4. Operating business segments
    • 8.2.5. Product portfolio
    • 8.2.6. Business performance
  • 8.3. Integra LifeSciences Holdings
    • 8.3.1. Company overview
    • 8.3.2. Key Executives
    • 8.3.3. Company snapshot
    • 8.3.4. Operating business segments
    • 8.3.5. Product portfolio
    • 8.3.6. Business performance
  • 8.4. Wellona Pharma
    • 8.4.1. Company overview
    • 8.4.2. Key Executives
    • 8.4.3. Company snapshot
    • 8.4.4. Operating business segments
    • 8.4.5. Product portfolio
  • 8.5. Delta Surgical
    • 8.5.1. Company overview
    • 8.5.2. Key Executives
    • 8.5.3. Company snapshot
    • 8.5.4. Operating business segments
    • 8.5.5. Product portfolio
  • 8.6. Spiegelberg GmbH & Co. KG
    • 8.6.1. Company overview
    • 8.6.2. Key Executives
    • 8.6.3. Company snapshot
    • 8.6.4. Operating business segments
    • 8.6.5. Product portfolio
  • 8.7. G. Surgiwear Ltd.
    • 8.7.1. Company overview
    • 8.7.2. Key Executives
    • 8.7.3. Company snapshot
    • 8.7.4. Operating business segments
    • 8.7.5. Product portfolio
  • 8.8. Moller Medical GmbH
    • 8.8.1. Company overview
    • 8.8.2. Key Executives
    • 8.8.3. Company snapshot
    • 8.8.4. Operating business segments
    • 8.8.5. Product portfolio
  • 8.9. Natus Medical Incorporated
    • 8.9.1. Company overview
    • 8.9.2. Key Executives
    • 8.9.3. Company snapshot
    • 8.9.4. Operating business segments
    • 8.9.5. Product portfolio
    • 8.9.6. Business performance
  • 8.10. Tokibo Co.,Ltd
    • 8.10.1. Company overview
    • 8.10.2. Key Executives
    • 8.10.3. Company snapshot
    • 8.10.4. Operating business segments
    • 8.10.5. Product portfolio

LIST OF TABLES

  • TABLE 01. GLOBAL CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 02. CEREBROSPINAL FLUID MANAGEMENT MARKET FOR CSF SHUNTS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 03. CEREBROSPINAL FLUID MANAGEMENT MARKET FOR EXTERNAL DRAINAGE SYSTEM, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 04. GLOBAL CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 05. CEREBROSPINAL FLUID MANAGEMENT MARKET FOR PEDIATRIC, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 06. CEREBROSPINAL FLUID MANAGEMENT MARKET FOR ADULT, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 07. CEREBROSPINAL FLUID MANAGEMENT MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 08. NORTH AMERICA CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 09. NORTH AMERICA CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 10. NORTH AMERICA CEREBROSPINAL FLUID MANAGEMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 11. U.S. CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 12. U.S. CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 13. CANADA CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 14. CANADA CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 15. MEXICO CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 16. MEXICO CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 17. EUROPE CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 18. EUROPE CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 19. EUROPE CEREBROSPINAL FLUID MANAGEMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 20. GERMANY CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 21. GERMANY CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 22. FRANCE CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 23. FRANCE CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 24. UK CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 25. UK CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 26. ITALY CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 27. ITALY CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 28. SPAIN CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 29. SPAIN CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 30. REST OF EUROPE CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 31. REST OF EUROPE CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 32. ASIA-PACIFIC CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 33. ASIA-PACIFIC CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 34. ASIA-PACIFIC CEREBROSPINAL FLUID MANAGEMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 35. CHINA CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 36. CHINA CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 37. JAPAN CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 38. JAPAN CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 39. INDIA CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 40. INDIA CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 41. AUSTRALIA CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 42. AUSTRALIA CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 43. SOUTH KOREA CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 44. SOUTH KOREA CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 45. REST OF ASIA-PACIFIC CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 46. REST OF ASIA-PACIFIC CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 47. LAMEA CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 48. LAMEA CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 49. LAMEA CEREBROSPINAL FLUID MANAGEMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 50. BRAZIL CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 51. BRAZIL CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 52. SAUDI ARABIA CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 53. SAUDI ARABIA CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 54. SOUTH AFRICA CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 55. SOUTH AFRICA CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 56. REST OF LAMEA CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 57. REST OF LAMEA CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021-2031 (REVENUE, $MILLION)
  • TABLE 58. MEDTRONIC PLC: KEY EXECUTIVES
  • TABLE 59. MEDTRONIC PLC: COMPANY SNAPSHOT
  • TABLE 60. MEDTRONIC PLC: PRODUCT SEGMENTS
  • TABLE 61. MEDTRONIC PLC: PRODUCT PORTFOLIO
  • TABLE 62. B. BRAUN MELSUNGEN AG: KEY EXECUTIVES
  • TABLE 63. B. BRAUN MELSUNGEN AG: COMPANY SNAPSHOT
  • TABLE 64. B. BRAUN MELSUNGEN AG: PRODUCT SEGMENTS
  • TABLE 65. B. BRAUN MELSUNGEN AG: PRODUCT PORTFOLIO
  • TABLE 66. INTEGRA LIFESCIENCES HOLDINGS: KEY EXECUTIVES
  • TABLE 67. INTEGRA LIFESCIENCES HOLDINGS: COMPANY SNAPSHOT
  • TABLE 68. INTEGRA LIFESCIENCES HOLDINGS: PRODUCT SEGMENTS
  • TABLE 69. INTEGRA LIFESCIENCES HOLDINGS: PRODUCT PORTFOLIO
  • TABLE 70. WELLONA PHARMA: KEY EXECUTIVES
  • TABLE 71. WELLONA PHARMA: COMPANY SNAPSHOT
  • TABLE 72. WELLONA PHARMA: PRODUCT SEGMENTS
  • TABLE 73. WELLONA PHARMA: PRODUCT PORTFOLIO
  • TABLE 74. DELTA SURGICAL: KEY EXECUTIVES
  • TABLE 75. DELTA SURGICAL: COMPANY SNAPSHOT
  • TABLE 76. DELTA SURGICAL: PRODUCT SEGMENTS
  • TABLE 77. DELTA SURGICAL: PRODUCT PORTFOLIO
  • TABLE 78. SPIEGELBERG GMBH & CO. KG: KEY EXECUTIVES
  • TABLE 79. SPIEGELBERG GMBH & CO. KG: COMPANY SNAPSHOT
  • TABLE 80. SPIEGELBERG GMBH & CO. KG: PRODUCT SEGMENTS
  • TABLE 81. SPIEGELBERG GMBH & CO. KG: PRODUCT PORTFOLIO
  • TABLE 82. G. SURGIWEAR LTD.: KEY EXECUTIVES
  • TABLE 83. G. SURGIWEAR LTD.: COMPANY SNAPSHOT
  • TABLE 84. G. SURGIWEAR LTD.: PRODUCT SEGMENTS
  • TABLE 85. G. SURGIWEAR LTD.: PRODUCT PORTFOLIO
  • TABLE 86. MOLLER MEDICAL GMBH: KEY EXECUTIVES
  • TABLE 87. MOLLER MEDICAL GMBH: COMPANY SNAPSHOT
  • TABLE 88. MOLLER MEDICAL GMBH: PRODUCT SEGMENTS
  • TABLE 89. MOLLER MEDICAL GMBH: PRODUCT PORTFOLIO
  • TABLE 90. NATUS MEDICAL INCORPORATED: KEY EXECUTIVES
  • TABLE 91. NATUS MEDICAL INCORPORATED: COMPANY SNAPSHOT
  • TABLE 92. NATUS MEDICAL INCORPORATED: PRODUCT SEGMENTS
  • TABLE 93. NATUS MEDICAL INCORPORATED: PRODUCT PORTFOLIO
  • TABLE 94. TOKIBO CO.,LTD: KEY EXECUTIVES
  • TABLE 95. TOKIBO CO.,LTD: COMPANY SNAPSHOT
  • TABLE 96. TOKIBO CO.,LTD: PRODUCT SEGMENTS
  • TABLE 97. TOKIBO CO.,LTD: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. CEREBROSPINAL FLUID MANAGEMENT MARKET, 2021-2031
  • FIGURE 02. SEGMENTATION OF CEREBROSPINAL FLUID MANAGEMENT MARKET, 2021-2031
  • FIGURE 03. TOP INVESTMENT POCKETS IN CEREBROSPINAL FLUID MANAGEMENT MARKET (2022-2031)
  • FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 06. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 07. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 08. MODERATE INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALCEREBROSPINAL FLUID MANAGEMENT MARKET
  • FIGURE 10. CEREBROSPINAL FLUID MANAGEMENT MARKET, BY TYPE, 2021(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF CEREBROSPINAL FLUID MANAGEMENT MARKET FOR CSF SHUNTS, BY COUNTRY 2021-2031(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF CEREBROSPINAL FLUID MANAGEMENT MARKET FOR EXTERNAL DRAINAGE SYSTEM, BY COUNTRY 2021-2031(%)
  • FIGURE 13. CEREBROSPINAL FLUID MANAGEMENT MARKET, BY AGE GROUP, 2021(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF CEREBROSPINAL FLUID MANAGEMENT MARKET FOR PEDIATRIC, BY COUNTRY 2021-2031(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF CEREBROSPINAL FLUID MANAGEMENT MARKET FOR ADULT, BY COUNTRY 2021-2031(%)
  • FIGURE 16. CEREBROSPINAL FLUID MANAGEMENT MARKET BY REGION, 2021
  • FIGURE 17. U.S. CEREBROSPINAL FLUID MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 18. CANADA CEREBROSPINAL FLUID MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 19. MEXICO CEREBROSPINAL FLUID MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 20. GERMANY CEREBROSPINAL FLUID MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 21. FRANCE CEREBROSPINAL FLUID MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 22. UK CEREBROSPINAL FLUID MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 23. ITALY CEREBROSPINAL FLUID MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 24. SPAIN CEREBROSPINAL FLUID MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 25. REST OF EUROPE CEREBROSPINAL FLUID MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 26. CHINA CEREBROSPINAL FLUID MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 27. JAPAN CEREBROSPINAL FLUID MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 28. INDIA CEREBROSPINAL FLUID MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 29. AUSTRALIA CEREBROSPINAL FLUID MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 30. SOUTH KOREA CEREBROSPINAL FLUID MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 31. REST OF ASIA-PACIFIC CEREBROSPINAL FLUID MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 32. BRAZIL CEREBROSPINAL FLUID MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 33. SAUDI ARABIA CEREBROSPINAL FLUID MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 34. SOUTH AFRICA CEREBROSPINAL FLUID MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 35. REST OF LAMEA CEREBROSPINAL FLUID MANAGEMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 36. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 37. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 38. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 39. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 40. COMPETITIVE DASHBOARD
  • FIGURE 41. COMPETITIVE HEATMAP: CEREBROSPINAL FLUID MANAGEMENT MARKET
  • FIGURE 42. TOP PLAYER POSITIONING, 2021
  • FIGURE 43. MEDTRONIC PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 44. MEDTRONIC PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 45. MEDTRONIC PLC: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 46. B. BRAUN MELSUNGEN AG: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 47. B. BRAUN MELSUNGEN AG: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 48. B. BRAUN MELSUNGEN AG: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 49. INTEGRA LIFESCIENCES HOLDINGS: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 50. INTEGRA LIFESCIENCES HOLDINGS: RESEARCH & DEVELOPMENT EXPENDITURE, 2019-2021
  • FIGURE 51. INTEGRA LIFESCIENCES HOLDINGS: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 52. INTEGRA LIFESCIENCES HOLDINGS: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 53. NATUS MEDICAL INCORPORATED: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 54. NATUS MEDICAL INCORPORATED: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 55. NATUS MEDICAL INCORPORATED: REVENUE SHARE BY REGION, 2021 (%)